明德生物
(002932)
| 流通市值：30.34亿 | | | 总市值：45.20亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 69,960,271.6 | 350,061,800.61 | 225,617,843.38 | 154,270,388.52 |
| 营业收入 | 69,960,271.6 | 350,061,800.61 | 225,617,843.38 | 154,270,388.52 |
| 二、营业总成本 | 114,191,703.22 | 432,523,176.2 | 319,893,245.81 | 212,168,994.95 |
| 营业成本 | 58,506,453.08 | 161,410,575.99 | 108,759,792.33 | 68,776,065.62 |
| 税金及附加 | 925,080.89 | 1,507,707.19 | 992,146.35 | 703,190.21 |
| 销售费用 | 18,619,395.34 | 85,322,167.97 | 78,658,773.4 | 54,932,921.56 |
| 管理费用 | 13,290,488.75 | 84,287,503.42 | 51,979,156.29 | 37,486,649.12 |
| 研发费用 | 24,550,271.02 | 109,551,499.12 | 86,244,236.06 | 55,224,582.79 |
| 财务费用 | -1,699,985.86 | -9,556,277.49 | -6,740,858.62 | -4,954,414.35 |
| 其中:利息费用 | 29,250 | 1,284,903.85 | 470,919.47 | - |
| 其中:利息收入 | 2,194,992.86 | 10,400,731.61 | 8,205,047.52 | 5,175,296.41 |
| 加:公允价值变动收益 | - | 1,736,551.64 | 637,059.61 | 637,059.61 |
| 加:投资收益 | 27,005,803.92 | 133,703,042.86 | 78,456,046.18 | 54,864,143.65 |
| 资产处置收益 | - | 1,792,048.58 | 82,278.11 | 310,788.39 |
| 资产减值损失(新) | - | -86,919,196.43 | 0 | 0 |
| 信用减值损失(新) | 14,258,490.11 | -4,007,552.47 | 26,852,344.74 | 1,899,068.8 |
| 其他收益 | 539,924.11 | 77,343,383.3 | 70,528,745.56 | 70,295,279.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -2,427,213.48 | 41,186,901.89 | 82,281,071.77 | 70,107,733.62 |
| 加:营业外收入 | 26,975.57 | 3,820,836.87 | 338,528.65 | 177,073.45 |
| 减:营业外支出 | 1,569,400.87 | 12,591,770.34 | 4,544,957.62 | 2,569,522.51 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -3,969,638.78 | 32,415,968.42 | 78,074,642.8 | 67,715,284.56 |
| 减:所得税费用 | -564,464.79 | 5,851,251.93 | 15,710,870.64 | 12,943,750.62 |
| 六、净利润 | -3,405,173.99 | 26,564,716.49 | 62,363,772.16 | 54,771,533.94 |
| 持续经营净利润 | -3,405,173.99 | 26,564,716.49 | 62,363,772.16 | 54,771,533.94 |
| 归属于母公司股东的净利润 | -3,662,988.06 | 74,519,615.72 | 80,938,367.97 | 65,162,572.86 |
| 少数股东损益 | 257,814.07 | -47,954,899.23 | -18,574,595.81 | -10,391,038.92 |
| (一)基本每股收益 | -0.02 | 0.33 | 0.35 | 0.28 |
| (二)稀释每股收益 | -0.02 | 0.33 | 0.35 | 0.28 |
| 九、综合收益总额 | -3,405,173.99 | 26,564,716.49 | 62,363,772.16 | 54,771,533.94 |
| 归属于母公司股东的综合收益总额 | -3,662,988.06 | 74,519,615.72 | 80,938,367.97 | 65,162,572.86 |
| 归属于少数股东的综合收益总额 | 257,814.07 | -47,954,899.23 | -18,574,595.81 | -10,391,038.92 |
| 公告日期 | 2025-04-30 | 2025-04-25 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |